There is a misperception in the U.S. that we have "conquered" heart disease and stroke, but the evidence shows that this is far from true.
Prescription rates dramatically decreased following the price hikes of Valeant's Isuprel and Nitropress in 47 hospitals.
Experts say this means drugmakers need to find new ways to communicate the value of their products.
Merck's CETP inhibitor anacetrapib and Novartis' monoclonal antibody ACZ885 hit their primary goals in late-stage cardiovascular outcomes trials, both unexpectedly positive results that are heating up this category.
Merck announces positive trial results for CETP inhibitor; Purdue Pharma defends withholding of OxyContin marketing material; Roche's experimental haemophilia drug significantly cuts bleed rate
Novartis drug prevents heart attacks and strokes, per trial; Senate lawmakers unveil healthcare bill; Pfizer receives CRL for Epogen biosimilar
The drugmaker said it has been forced to provide higher rebates to PBMs and insurers for certain drugs.
Study finds SGLT-2 inhibitors lowered risk of death; former FDA commissioners raise drug importation issues; Bayer, J&J's Xarelto lowered VTE risk in study
Amgen said it would offer payers a refund for patients who have a heart attack or stroke while taking the PCSK9 inhibitor.
Repatha reduces need for time-consuming procedure; Trump selects Gottlieb to lead the FDA; Acorda launches Alexa skill for MS
The new spot for its cholesterol-lowering injection debuted last week.
Court to allow Sanofi and Regeneron to market Praluent during appeal; Xarelto is effective in treating artery disease; VP advocates for right-to-try laws
Trial finds that Repatha reduces risk of heart attack and stroke; California measure would ban drug coupons in some cases; Takeda to limit price increases
J&J to buy Actelion for $30 billion; Pfizer fights advertising ban related to Advil; almost half of women with breast cancer report severe side effects
The first two PCSK9s landed with a thud. What does their disappointing launch say about the need for marketers of CV drugs to get their pricing houses in order?
Despite their blockbuster status and distinction as the world's most widely prescribed class of drugs, statins may not be the best option for all patients with elevated low density lipoprotein (LDL) cholesterol levels.
The top-selling heart drug is Merck's Zetia, which is expected to bring in about $1.68 billion in sales in 2016.
Judge halts Praluent sales; clinical-trial data for Diclegis in question; cancer drugs to make up larger portion of total drug spending
The heart is a tireless worker, beating day and night. When we're telling stories for healthcare brands, we should remember what it takes to infuse real feeling, to get people to care.
J&J's experimental RA drug has mixed results in clinical trial; Novartis reportedly considers buying generics maker; Donald Trump names healthcare transition team leader
Denise Strauss, formerly VP of cardiovascular marketing at Boehringer Ingelheim, will oversee the drugmaker's marketing activities.
And why the stories behind thalidomide, Naprosyn, AZT, cardiology stents, and Zaltrap still resonate.
The app's co-founder discusses how it's educating patients and physicians about artificial intelligence and why Cardiogram is different from other heart-rate tracking apps.
New Cigna campaign features TV doctors; Walgreens to divest 1,000 stores; senators question Aetna's health exchange exit
Walgreens Boots partners with PBM; Clinton proposes mental health plan; BI and Qualcomm to develop connected inhaler
The new company, iBeat, plans to market a wearable device that can detect the symptoms of cardiac arrest and heart attacks.
Novartis plans new trials for Entresto; U.S. spending on mental health topped $201 billion in 2013; the FDA approves Roche's immunotherapy drug
Valeant has not delivered promised price breaks on heart drugs; AstraZeneca drug receives orphan status; Allergan promotes Meury and Stewart
Entresto's sales are still lower than expected; GSK CEO Witty to retire in 2017; tech assistants sometimes fail to account for women's health needs
It's possible that payers won't prove the wild card in the PCSK9 derby. Instead, physician preference may do more to shape the market and maybe even force payers' hands.